PharmaBio concluded an agreement with Nagoya City University to conduct a “clinical trial on human (allogenic) subcutaneous adipose tissue derived mesenchymal stem cell sheet (PAL-222) transplantation for myopic chorioretinal atrophy”. This time, we would like to inform you that PAL-222 was successfully transplanted to the first patient in a Phase 1/2a clinical study (PAMyCA Study).
For inquiries regarding this matter, please contact the following.
Director, General Manager of Project Promotion Department：Toshihiko Sugioka
E-mail：ir_admin@pharmabio.co.jp